Reply to “Distinguishing the Fibrosis-3 Index From FIB-4 Without Age: Clarification and an Invitation for External Validation”
Clinical Gastroenterology and Hepatology · 2026-11
DOI: 10.1016/j.cgh.2026.10.024 ↗Kurz gefasst
Leserbrief in der Zeitschrift Clinical Gastroenterology and Hepatology, 2026-11. Verfasst von Jeevan Nammi und 1 weiteren Autor:innen. Beteiligte Einrichtung: Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Autor:innen und Institutionen
- Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA.
- Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA; UAB Comprehensive Diabetes Center, University of Alabama at Birmingham, Birmingham, A…
Zitieren
APA
Nammi, J., & Bril, F. (2026). Reply to “Distinguishing the Fibrosis-3 Index From FIB-4 Without Age: Clarification and an Invitation for External Validation”. Clinical Gastroenterology and Hepatology. https://doi.org/10.1016/j.cgh.2026.10.024
Vancouver
Nammi J, Bril F. Reply to “Distinguishing the Fibrosis-3 Index From FIB-4 Without Age: Clarification and an Invitation for External Validation”. Clinical Gastroenterology and Hepatology. 2026. doi:10.1016/j.cgh.2026.10.024
BibTeX
@article{Nammi2026,
author = {Nammi, Jeevan and Bril, Fernando},
title = {Reply to “Distinguishing the Fibrosis-3 Index From FIB-4 Without Age: Clarification and an Invitation for External Validation”},
journal = {Clinical Gastroenterology and Hepatology},
year = {2026},
doi = {10.1016/j.cgh.2026.10.024}
}
EUVIMED